This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Fig. 1. (A) At the time of the first visit, the primary complaints were hyperpigmentation and hypertrichosis in the periocular area. Also note the increased length of the eyelashes. (B) Six months after discontinuation of travoprost. Note the decreased pigmentation in the periocular area. Also, the length and density of both the hairs of the periocular area and the eyelashes are reduced.
Fig. 1. (A)
At the time of the first visit, the primary complaints were hyperpigmentation and hypertrichosis in the periocular area. Also note the increased length of the eyelashes. (B) Six months after discontinuation of travoprost. Note the decreased pigmentation in the periocular area. Also, the length and density of both the hairs of the periocular area and the eyelashes are reduced. A 53-year-old Korean man presented with recently recognized hypertrichosis and hyperpigmentation in the periocular area. He had a history of bilateral primary open-angle glaucoma for 7 years and has been treated with a regimen including topical 0.005% latanoprost (Xalatan; Pfizer Inc., New York, NY, USA). About 4 months before the visit, the topical agent was changed to another PGA, 0.004% travoprost (Travatan; Alcon Inc., Fort Worth, TX, USA). Within 3 months of switching the medication to travoprost, the patient noticed hyperpigmentation, hair growth around both eyes, and trichomegaly of the eyelashes (Fig. 1A) . The histopathologic findings showed hyperpigmentation on the basal layer of the epidermis. Travoprost, suspected as the most causative drug, was ceased, and it was recommended to resume medication with latanoprost. Six months later, these adverse events showed gradual improvement, indicating that they are reversible (Fig. 1B) . Increase in length of the eyelashes and periocular skin pigmentation have been commonly reported in patients with open-angle glaucoma treated with PGAs 1,2 . Less comparative studies exist on the tolerability and incidence of local adverse effects of travoprost. However, as travoprost and latanoprost are both ester prodrugs of prostaglandin F2-α, the adverse effects might develop through similar mechanisms. Periocular hyperpigmentation is thought to occur because of increased melanogenesis and melanocyte proliferation induced by PGAs, or contact dermatitis-like reaction might play some contributory role 1 . Hypertrichosis of the eyelashes is considered to be associated with the role of PGA of inducing anagen in follicles normally in telogen, in addition to inducing hypertrophic changes in the follicles. Furthermore, a prolonged anagen phase of the hair cycle is likely to increase the length of the eyelashes. Although PGA-induced hypertrichosis primarily involves the eyelashes, it has also been reported to affect the adjacent adnexal hair 4, 5 . Ortiz-Perez and Olver 5 reported hypertrichosis of both upper cheeks 3 months after using travoprost, and suggested the possibility of missing the exact site for drug application because of the patient's old age. In our case, the patient had motor impairment that might have led to the application of the drug outside of the eye. As a result, hypertrichosis and hyperpigmentation in the periocular area, and eyelash growth were observed. However, because travoprost and latanoprost act with similar mechanisms, the finding that adverse effects occurred only with travoprost in our case is somewhat questionable. This might be explained by the evidence showing that the free acids of travoprost are 10 times more potent in activating the prostaglandin F receptor than latanoprost free acid 1 . Thus, this activation of travoprost might have a greater influence on hair growth and melanogenesis than latanoprost. Despite the great efficacy of travoprost, these local adverse effects can cause frustrating discomfort to patients, thus affecting their treatment compliance. In conclusion, physicians should be aware of all possible adverse effects of the drug, and patients should be reassured about the reversibility of these adverse effects.
